

**NOVEL DRUG DELIVERY CARRIER SYSTEM: - A UPDATED  
REVIEW**

**Punet Kumar<sup>1\*</sup>, Md Iftekhhar Ahmad<sup>1</sup>, Sangam<sup>2</sup>, Vidhan Chand Bala<sup>2</sup>, Deepti Aggarwal<sup>2</sup> and Manisha Kumari<sup>3</sup>**

<sup>1</sup>Faculty of Shri Gopichand College of Pharmacy, Baghpat, 250609, (U. P.) India.

<sup>2</sup>Faculty of Oxford College of Pharmacy, Hapur, 201001, (U.P.) India.

<sup>3</sup>Vishveshwarya Group of Institutions, G.B. Nagar, (U.P.) India.

Article Received on  
05 August 2019,

Revised on 26 August 2019,  
Accepted on 16 Sept. 2019

DOI: 10.20959/wjpr201911-15880

**\*Corresponding Author**

**Prof. Punet Kumar**

Faculty of Shri Gopichand  
College of Pharmacy,  
Baghpat, 250609, (U. P.)  
India.

**ABSTRACT**

The best candidates for controlling the drug delivery system are those who do not absorb the stomach or intestines, including peptides. Medicines used to treat IBD, ulcerative colitis, diarrhea, and colon cancer are ideal candidates for local colon delivery. The conjugation of biological (peptide / protein) and synthetic polymers is an effective tool to improve control over the formation of nano scale structures of synthetic polymeric materials that can be used as drug delivery systems. Other approaches to medication are focused on overcoming specific physical barriers, such as the blood-brain barrier, to better target medications and improve their effectiveness or find alternative

and acceptable ways to use protein drugs, except through the gastrointestinal system, where degradation may occur. The advantage of the way of drug delivery useful for other types of drug delivery, such as oral, topical root, intravenous, intramuscular, etc.

**KEYWORDS:** Pharmacological class, Pharmacodynamics, Peptide drugs, Carriers, Administration route, synthetic polymers.

**INTRODUCTION**

The method of delivery of medicines can have a significant impact on its effectiveness. Some medicines have high levels of internalization that produce high efficacy, and concentrations above or below this drug may be toxic or have therapeutic benefits. On the other hand, the very slow progress in the effectiveness of the treatment of serious illnesses implies an increasing need for a multidisciplinary approach in delivering therapists to tissue targets.

From this, new ideas have been generated regarding the control of pharmacokinetics, Pharmacodynamics, non-specific toxicity, immunogenicity, and bio-knowledge and drug efficacy. These new strategies, often called drug delivery systems (DDS), are based on interdisciplinary approaches that combine polymer science, pharmaceutics, bio-conjugate chemistry, and molecular biology.<sup>[1]</sup>

In order to minimize drug degradation and loss to prevent adverse side effects and increase drug bioavailability and accumulated drug fraction in the required area, different drug delivery and targeting systems are currently being developed. Drug carriers may include soluble polymers, micro particles made from insoluble or biodegradable natural and synthetic polymers, microarrays<sup>[2]</sup> microcapsules, cells, phantom cells, lipoproteins, liposome's and micelles. Carriers can be made slowly degradable, stimulating stimulants (e.g., pH or temperature-sensitive) and even targeted<sup>[3]</sup> (e.g., by combining with specific antibodies against specific characteristic components, area of interest). The goal is the ability to redirect a drug-loaded system to a site of interest to you. Two main mechanisms can be distinguished for determining desired drug release sites: (i) passive and (ii) active targeting. An example of a passive focus is the governing accumulation of chemotherapeutic agents in solid tumors as a result of an increased penetration of tumor tissue compared to healthy tissue.

One strategy that may allow active targeting involves the transport of a fictitious drug ligand selectively recognized by receptors across interesting cells. Because the ligand–receptor interactions can be quite selective, this may allow more precise targeting of the site of interest. Controlled drug delivery and subsequent biodegradation are important for the development of successful formulations. Possible delivery mechanisms include: (i) adsorption of bound / adsorbed drugs; (ii) diffusion through a force matrix; (iii) diffusion (in the case of nano-capsules) through the carrier wall; (iv) Erosion of carrier matrices and (v) a combined grinding / diffusion process. The method of administration can be the difference between the success and failure of a medication, because the choice of a medication is often influenced by the way the medication is administered. The sustained (or continuous) release of a drug includes polymers that release the drug at a controlled rate due to polymer diffusion or polymer degradation over time. Palatial release is often the preferred method of drug delivery because it mimics the way the body naturally produces hormones such as insulin. This is achieved through the use of drug-bearing polymers that respond to specific stimuli (for example, exposure to light, changes in pH or temperature).

For more than 20 years, scientists have been recognizing the potential benefits of nanotechnology that can provide significant improvements in medication administration and targeting. Improving administration techniques that reduce toxicity and improve its effectiveness offer enormous potential benefits for patients and open up new markets for pharmaceutical companies and drug providers. Other approaches to drug administration focus on crossing certain physical barriers, such as the blood brain barrier, to better target the medication and improve its effectiveness; or look for alternative and acceptable methods for administering non-gastrointestinal protein drugs in which degradation may occur.<sup>[4]</sup>

### **Advantages of a controlled drug delivery system in a conventional dosage form**

1. Improved patient convenience and compliance due to less frequent drug administration.
2. Reduction in fluctuation in steady – state levels and therefore-
  - Better control of disease condition and
  - Reduced intensity of local or systemic side effects
3. Increased safety margin of high potency drugs due to better control of plasma levels.
4. Maximum utilization of drug enabling reduction in total amount of dose administered.
5. Reduction in health care cost through-
  - Improved therapy.
  - Shorter treatment period.
  - Lower frequency of dosing.

### **Disadvantages of controlled drug delivery system**

1. Decreased systemic availability in comparison to immediate release conventional dosage forms. this may be due to-
  - a. Incomplete release.
  - b. Increased first pass metabolism.
  - c. Increased instability.
  - d. Site specific absorption.
  - e. pH dependent solubility.
2. Poor in vitro- in vivo correlation.
3. Reduced potential for dosage adjustment of drugs normally administered in varying strengths.
4. Higher cost of formulation.

### Criteria for Selection of Drug for CDDS

The best Candidates for CDDS are drugs which show poor absorption from the stomach or intestine including peptides. The drugs used in the treatment of IBD, ulcerative colitis, diarrhea, and colon cancer are ideal candidates for local colon delivery.<sup>[5]</sup> the criteria for selection of drugs for CDDS are summarized in Table.<sup>[6]</sup> Drug Carrier is another factor which influences CDDS. The selection of carrier for particular drugs depends on the physiochemical nature of the drug as well as the disease for which the system is to be used. Factors such as chemical nature, stability and partition coefficient of the drug and type of absorption enhancer chosen influence the carrier selection. Moreover, the choice of drug carrier depends on the functional groups of the drug molecule. For example, aniline or nitro groups on a drug may be used to link it to another benzene group through an azo bond. The carriers, which contain additives like polymers (may be used as matrices and hydro gels or coating agents) may influence the release properties and efficacy of the system.<sup>[7]</sup>

**Table 1: Criteria for selection of drugs for CDDS.**

Criteria	Pharmacological class	Non-peptide drugs	Peptide drugs
Drugs used for local effects in colon against GIT diseases	Anti-inflammatory drugs	Oxyprenolol, Metoprolol, Nifedipine	Amylin, Antisense oligonucleotide
Drugs poorly absorbed from upper GIT Drugs for colon cancer Drugs that degrade in stomach and small intestine	Antihypertensive and antianginal drugs Antineoplastic drugs Peptides and proteins	Ibuprofen, Isosorbides Theophylline Pseudoephedrine Bromophenaramine, 5-Flourouracil, Doxorubicin Bleomycin, Nicotine	Cyclosporine, Desmopressin Epoetin, Glucagon Gonadoreline, Insulin, Interferons Protirelin,sermorelin,
Drugs that undergo extensive first pass metabolism	Nitroglycerin and corticosteroids	Prednisolone, hydrocortisone,	Saloatonin
Drugs for targeting	Antiarthritic and antiasthamatic drugs	5-Amino-salicylic acid	Somatropin,Urotoilitin

### DRUG DELIVERY CARRIERS

Colloidal drug carrier systems such as micellar solutions, vesicle and liquid crystal dispersions, as well as nanoparticle dispersions consisting of small particles of 10–400 nm diameter show great promise as drug delivery systems. When developing these formulations, the goal is to obtain systems with optimized drug loading and release properties, long shelf-life and low toxicity. The incorporated drug participates in the microstructure of the system, and may even influence it due to molecular interactions, especially if the drug possesses amphiphilic and/or mesogenic properties.<sup>[8]</sup>

Micelles formed by self-assembly of amphiphilic block copolymers (5-50 nm) in aqueous solutions are of great interest for drug delivery applications. The drugs can be physically entrapped in the core of block copolymer micelles and transported at concentrations that can exceed their intrinsic water- solubility. Moreover, the hydrophilic blocks can form hydrogen bonds with the aqueous surroundings and form a tight shell around the micellar core. As a result, the contents of the hydrophobic core are effectively protected against hydrolysis and enzymatic degradation. In addition, the corona may prevent recognition by the reticuloendothelial system and therefore preliminary elimination of the micelles from the bloodstream. A final feature that makes amphiphilic block copolymers attractive for drug delivery applications is the fact that their chemical composition, total molecular weight and block length ratios can be easily changed, which allows control of the size and morphology of the micelles. Fictionalization of block copolymers with crosslink able groups can increase the stability of the corresponding micelles and improve their temporal control. Substitution of block copolymer micelles with specific ligand is a very promising strategy to a broader range of sites of activity with a much higher selectivity.<sup>[9]</sup>

Liposome is a form of vesicles that consist either of many, few or just one phospholipid bilayer. The polar character of the liposomal core enables polar drug molecules to be encapsulated. Amphiphiles and lipophilic molecules are solubilising within the phospholipid bilayer according to their affinity towards the phospholipids. Participation of nonionic surfactants instead of phospholipids in the bilayer formation results in noisome. Channel proteins can be incorporated without loss of their activity within the hydrophobic domain of vesicle membranes, acting as a size-selective filter, only allowing passive diffusion of small solutes such as ions, nutrients and antibiotics. Thus, drugs that are encapsulated in a nanocage-functionalized with channel proteins are effectively protected from premature degradation by proteolytic enzymes. The drug molecule, however, is able to diffuse through the channel, driven by the concentration difference between the interior and the exterior of the nanocage.<sup>[10]</sup>

Dendrimers are nanometer-sized, highly branched and monodisperse macromolecules with symmetrical architecture. They consist of a central core, branching units and terminal functional groups. The core together with the internal units, determine the environment of the nanocavities and consequently their solubilizing properties, whereas the external groups the solubility and chemical behavior of these polymers. Targeting effectiveness is affected by

attaching targeting ligand at the external surface of dendrimers, while their stability and protection from the Mononuclear Phagocyte System (MPS) is being achieved by fictionalization of the dendrimers with polyethylene glycol chains (PEG). Liquid Crystals combine the properties of both liquid and solid states. They can be made to form different geometries, with alternative polar and non-polar layers (i.e., a lamellar phase) where aqueous drug solutions can be included.<sup>[11]</sup>

Nanoparticle (including nanospheres and nanocapsules of size 10-200 nm) are in the solid state and are either amorphous or crystalline. They are able to absorb and/or encapsulate a drug, thus protecting it against chemical and enzymatic degradation. Nanocapsules are vesicular systems in which the drug is confined to a cavity surrounded by a unique polymer membrane, while nanospheres are matrix systems in which the drug is physically and uniformly dispersed. Nanoparticles as drug carriers can be formed from both biodegradable polymers and non-biodegradable polymers. In recent years, biodegradable polymeric nanoparticle have attracted considerable attention as potential drug delivery devices in view of their applications in the controlled release of drugs, in targeting particular organs / tissues, as carriers of DNA in gene therapy, and in their ability to deliver proteins, peptides and genes through the per oral route hydro gels are three-dimensional, hydrophilic, polymeric networks capable of imbibing large amounts of water or biological fluids. The networks are composed of homopolymers or copolymers, and are insoluble due to the presence of chemical crosslink's (tie-points, junctions), or physical crosslink's, such as entanglements or crystallites. Hydro gels exhibit a thermodynamic compatibility with water, which allows them to swell in aqueous media. They are used to regulate drug release in reservoir-based, controlled release systems or as carriers in sellable and swelling-controlled release devices. On the forefront of controlled drug delivery, hydro gels as enviro-intelligent and stimuli-sensitive gel systems modulate release in response to pH, temperature, ionic strength, electric field, or specific analyze concentration differences.<sup>[12]</sup> In these systems, release can be designed to occur within specific areas of the body (e.g., within a certain pH of the digestive tract) or also via specific sites (adhesive or cell-receptor specific gels via tethered chains from the hydro gel surface). Hydro gels as drug delivery systems can be very promising materials if combined with the technique of molecular imprinting.<sup>[13]</sup>

The molecular imprinting technology has an enormous potential for creating satisfactory drug dosage forms. Molecular imprinting involves forming a pre-polymerization complex between

the template molecule and functional monomers or functional oligomers (or polymers) with specific chemical structures designed to interact with the template either by covalent, non-covalent chemistry (self-assembly) or both.<sup>[16]</sup> Once the pre-polymerization complex is formed, the polymerization reaction occurs in the presence of a cross-linking monomer and an appropriate solvent, which controls the overall polymer morphology and macroporous structure. Once the template is removed, the product is a heteropolymer matrix with specific recognition elements for the template molecule.<sup>[14]</sup>

Examples of MIP-based drug delivery systems involve: (i) rate-programmed drug delivery, where drug diffusion from the system has to follow a specific rate profile, (ii) activation-modulated drug delivery, where the release is activated by some physical, chemical or biochemical processes and (iii) feedback-regulated drug delivery, where the rate of drug release is regulated by the concentration of a triggering agent, such as a biochemical substance, the concentration of which is dependent on the drug concentration in the body. Despite the already developed interesting applications of MIPs, the incorporation of the molecular imprinting approach for the development of DDS is just at its incipient stage. Nevertheless, it can be foreseen that, in the next few years, significant progress will occur in this field, taking advantage of the improvements of this technology in other areas. Among the evolution lines that should contribute more to enhance the applicability of imprinting for drug delivery, the application of predictive tools for a rational design of imprinted systems and the development of molecular imprinting in water may be highlighted.<sup>[15]</sup>

Conjugation of biological (peptides/proteins) and synthetic polymers is an efficient means to improve control over nanoscale structure formation of synthetic polymeric materials that can be used as drug delivery systems. Conjugation of suitable biocompatible polymers to bioactive peptides or proteins can reduce toxicity, prevent immunogenic or antigenic side reactions, enhance blood circulation times and improve solubility. Modification of synthetic polymers or polymer therapeutics with suitable oligopeptide sequences, on the other hand, can prevent random distribution of drugs throughout a patient's body and allow active targeting. Fictionalization of synthetic polymers or polymer surfaces with peptide sequences derived from extracellular matrix proteins is an efficient way to mediate cell adhesion. The ability of cationic peptide sequences to complex and condense DNA and oligonucleotides offers prospects for the development of non-viral vectors for gene-delivery based on synthetic polymeric hybrid materials.<sup>[16]</sup>



The field of in-situ forming implants has grown exponentially in recent years. Liquid formulations generating a (semi-)solid depot after subcutaneous injection, also designated as implants, is an attractive delivery system for parenteral application because; they are less invasive and painful compared to implants. Localized or systemic drug delivery can be achieved for prolonged periods of time, typically ranging from one to several months. Generally, parental depot systems could minimize side effects by achieving constant, 'infusion-like' plasma-level time profiles, especially important for proteins with narrow therapeutic indices. From a manufacturing point of view, in-situ forming depot systems offer the advantage of being relatively simple to manufacture from polymers. Injectable in-situ forming implants are classified into four categories, according to their mechanism of depot formation: (i) thermoplastic pastes, (ii) in-situ cross-linked polymer systems, (iii) in-situ polymer precipitation, and (iv) there manly induced gelling systems.<sup>[17-18]</sup>

The ultimate goal in controlled release is the development of a micro fabricated device with the ability to store and release multiple chemical substances on demand. Recent advances in micro electro-mechanical systems (MEMS) have provided a unique opportunity to fabricate miniature biomedical devices for a variety of applications ranging from implantable drug delivery systems to lab-on-a-chip devices. The controlled release microchip has the following advantages: (i) multiple chemicals in any form (e.g., solid, liquid or gel) can be stored inside and released from the microchip, (ii) the release of chemicals is initiated by the disintegration of the barrier membrane via the application of an electric potential, (iii) a variety of highly potent drugs can potentially be delivered accurately and in a safe manner, (iv) complex release patterns (e.g., simultaneous constant and palatial release) can be achieved, (v) the microchip can be made small enough to make local chemical delivery possible thus achieving high concentrations of drug at the site where it is needed while keeping the systemic concentration of the drug at a low level and (vi) water penetration into the reservoirs is avoided by the barrier membrane and thus the stability of protein-based drugs with limited shelf-life is enhanced.<sup>[19]</sup>

### **Administration Routes**

The choice of a delivery route is driven by patient acceptability, the properties of the drug (such as its solubility), access to a disease location, or effectiveness in dealing with the specific disease. The most important drug delivery route is per oral route. An increasing number of drugs are protein-and peptide-based. They offer the greatest potential for more



effective therapeutics, but they do not easily cross mucosal surfaces and biological membranes; they are easily denatured or degraded, prone to rapid clearance in the liver and other body tissues and require precise dosing. At present, protein drugs are usually administered by injection, but this route is less pleasant and also poses problems of oscillating blood drug concentrations. So, despite the barriers to successful drug delivery that exist in the gastrointestinal tract (i.e., acid-induced hydrolysis in the stomach, enzymatic degradation throughout the gastrointestinal tract by several proteolysis enzymes, bacterial fermentation in the colon), the per oral route is still the most intensively investigated as it offers advantages of convenience and cheapness of administration, and potential manufacturing cost savings.<sup>[20]</sup>

Pulmonary delivery is also important and is effected in a variety of ways - via aerosols, metered dose inhaler systems (MDIs), powders (dry powder inhalers, DPIs) and solutions (nebulizers), all of which may contain nanostructures such as liposome's, micelles, nanoparticle and dendrites. Aerosol products for pulmonary delivery comprise more than 30% of the global drug delivery market. Research into lung delivery is driven by the potential for successful protein and peptide drug delivery, and by the promise of an effective delivery mechanism for gene therapy (for example, in the treatment of cystic fibrosis), as well as the need to replace chlorofluorocarbon propellants in MDIs. Pulmonary drug delivery offers both local targeting for the treatment of respiratory diseases and increasingly appears to be a viable option for the delivery of drugs systemically. However, the pulmonary delivery of proteins suffers by proteases in the lung, which reduce the overall bioavailability, and by the barrier between capillary blood and alveolar air (air-blood barrier).<sup>[21-22]</sup>

Transdermal drug delivery avoids problems such as gastrointestinal irritation, metabolism, variations in delivery rates and interference due to the presence of food. It is also suitable for unconscious patients. The technique is generally non-invasive and aesthetically acceptable, and can be used to provide local delivery over several days. Limitations include slow penetration rates, lack of dosage flexibility and / or precision, and a restriction to relatively low dosage drugs.<sup>[23-24]</sup>

Parenteral routes (intravenous, intramuscular, subcutaneous) are very important. The only nanosystems presently in the market (liposomes) are administered intravenously. Nano-scale drug carriers have a great potential for improving the delivery of drugs through nasal and sublingual routes, both of which avoid first-pass metabolism; and for difficult-access ocular,

brain and intra-particle cavities. For example, it has been possible to deliver peptides and vaccines systemically, using the nasal route, thanks to the association of the active drug macromolecules with nanoparticle. In addition, there is the possibility of improving the ocular bioavailability of drugs if administered in a colloidal drug carrier.<sup>[25-26]</sup>

Trans-tissue and local delivery systems require to be tightly fixed to respected tissues during surgery. The aim is to produce an elevated pharmacological effect, while minimizing systemic, administration-associated toxicity. Trans-tissue systems include: drug-loaded gelatinous gels, which are formed in-situ and adhere to respected tissues, releasing drugs, proteins or gene-encoding adenoviruses; antibody-fixed gelatinous gels (cytokine barrier) that form a barrier, which, on a target tissue could prevent the permeation of cytokines into that tissue; cell-based delivery, which involves a gene-transducer oral mucosal epithelial cell (OMEC)-implanted sheet; device-directed delivery - a rechargeable drug infusion device that can be attached to the respected site. Gene delivery is a challenging task in the treatment of genetic disorders. In the case of gene delivery, the plasmid DNA has to be introduced into the target cells, which should get transcribed and the genetic information should ultimately be translated into the corresponding protein. To achieve this goal, a number of hurdles are to be overcome by the gene delivery system. Transfection is affected by: (a) targeting the delivery system to the target cell, (b) transport through the cell membrane, (c) uptake and degradation in the endolysosomes and (d) intracellular trafficking of plasmid DNA to the nucleus.<sup>[27-28]</sup>

## RECENT ADVANCEMENT

Noisome are non-ionic surfactant vesicles which are used as drug carriers for encapsulating both hydrophilic and hydrophobic drugs. The aim of this study is to detect the effect of different surfactants on the physical properties and stability of carvedilol noisome designed to improve oral bioavailability. Bile acids are biological surfactants and signaling molecules having important endocrine and peregrine functions. The enter hepatic organ tropism of bile acids turns these facial amphiphiles into attractive drug delivery systems for selective drug targeting to the liver or to increase drug bioavailability by increasing intestinal absorption and stable metabolism.<sup>[29-30]</sup>

## CONCLUSION

Improving delivery techniques that minimize toxicity and improve efficacy offers great potential benefits to patients, and opens up new markets for pharmaceutical and drug delivery companies. Other approaches to drug delivery are focused on crossing particular physical

barriers, such as the blood brain barrier, in order to better target the drug and improve its effectiveness; or on finding alternative and acceptable routes for the delivery of protein drugs other than via the gastro-intestinal tract, where degradation can occur. . An advantage of a transdermal drug delivery route over other types of medication delivery such as oral, topical, intravenous, intramuscular, etc. is that the patch provides a controlled release of the medication into the patient, usually through either a porous membrane covering a reservoir of medication or through body heat melting thin layers of medication embedded in the adhesive.

### CONFLICT OF INTEREST

Author has no conflict of interest.

### REFERENCES

1. Charman WN, Chan HK, Finnin BC, Charman SA. Drug Delivery: A Key Factor in Realising the Full Therapeutic Potential of Drugs. *Drug Development Research*, 1999; 46: 316-27.
2. Santini JR, Richards AC, Scheidt R, Cima MJ. Langer R. Microchips as Controlled Drug-Delivery Devices. *Angew. Chem. Int. Ed.*, 2000; 39: 2396-407.
3. Kopecek J. Smart and genetically engineered biomaterials and drug delivery systems. *European Journal of Pharmaceutical Sciences*, 2003; 20: 1-16.
4. Bussemer T, Otto I, Bodmeier R. Pulsatile drug-delivery systems. *Crit Rev Ther Drug Carr Sys*, 2001; 18: 433-458.
5. Vyas SP, Khar RK. Gastroretentive systems. In: Vyas SP, Khar RK, editors. Controlled drug delivery: concepts and advances. New Delhi: *Vallabh Prakashan*, 2005; 218-253.
6. Antonin KH, Rak R, Bieck PR, Preiss R, Schenker U, Hastewell J, Fox R, Mackay M, The absorption of human calcitonin from the transverse colon of man. *Int J Pharm.*, 1996; 0(1): 33-39.
7. Fara JW. *Novel Drug Delivery and its Therapeutic Application*. In: Presscot LF, Nimmo WS, editors. Colonic drug absorption and metabolism. Wiley: Chichester, 1989; 103-120.
8. Friend DR, Chang GW. A colon-specific drug delivery system based on drug glycosides and glycosidase of colonic bacteria. *J Med Chem.*, 1984; 27: 261- 266.
9. Torchilin VP. Structure and design of polymeric surfactant-based drug delivery systems. *Journal of Controlled Release*, 2001; 73: 137-72.
10. Haag R. *Supramolecular Drug-Delivery Systems based on Polymeric Core-Shell Architectures*. *Angew. Chem. Int. Ed.*, 2004; 43: 278-82.

11. Soppimath KS, Aminabhavi TM, Kulkarni AR, Rudzinski WE. Biodegradable polymeric nanoparticles as drug delivery devices. *Journal of Controlled Release*, 2001; 70: 1-20.
12. Packhaeuser CB, Schnieders J, Oster CG, Kissel T. In situ forming parenteral drug delivery systems: an overview. *European Journal of Pharmaceutics and Biopharmaceutics*, 2004; 58: 445-55.
13. Agnihotri SA, Mallikarjuna NN, Aminabhavi TM. Recent advances on chitosan-based micro- and nanoparticles in drug delivery. *Journal of Controlled Release*, 2004; 100: 5-28.
14. Niculescu-Duvaz I, Springer CJ. Antibody-directed enzyme prodrug therapy (ADEPT): a review. *Advanced Drug Delivery Reviews*, 1997; 26: 151-72.
15. Manabe T, Okino H, Maeyama R, Mizumoto K, Nagai E, Tanaka M, Matsuda T. Novel strategic therapeutic approaches for prevention of local recurrence of pancreatic cancer after resection: trans-tissue, sustained local drug-delivery systems. *Journal of Controlled Release*, 2004; 100: 317-330.
16. Vandermeulen GWM, Klok HA. Peptide/Protein Hybrid Material: Enhanced Control of Structure and Improved Performance through Conjugation of Biological and Synthetic Polymers. *Macromolecular Bioscience*, 2003; 4: 383-98.
17. Alvarez-Lorenzo C, Concheiro A. Molecular imprinted polymers for drug delivery. *Journal of Chromatography B.*, 2004; 80(4): 231-245.
18. Vasir JK, Tambwekar K, Garg S. Bioadhesive microspheres as a controlled drug delivery system. *International Journal of Pharmaceutics*, 2003; 255: 13-32.
19. Bae Y, Fukushima S, Harada A, Kataoka K. *Design of Environment-Sensitive Supramolecular Assemblies for Intracellular Drug Delivery: Polymeric Micelles that are Responsive to Intracellular pH Change*. Angew. Chem. Int. Ed., 2003; 42: 4640-43.
20. Taymouri S, Varshosaz J. Effect of different types of surfactants on the physical properties and stability of carvedilol nano-niosomes. *Adv. Biomed. Res.*, 2016; 16: 5-48.
21. Faustino C, Serafim C, Rijo P, Reis CP. Bile acids and bile acid derivatives: use in drug delivery systems and as therapeutic agents. *Expert Opin. Drug Deliv*, 2016.
22. Tiwari G, Tiwari R, Sriwastawa B, Bhati L, Pandey S, Pandey P, Bannerjee SK. Drug delivery systems: An updated review. *International journal of pharmaceutical investigation*, Jan, 2012; 2(1): 2.
23. Gupta U, Agashe HB, Asthana A, Jain NK. A review of in vitro–in vivo investigations on dendrimers: the novel nanoscopic drug carriers. *Nanomedicine: Nanotechnology, Biology and Medicine*, Jun 1, 2006; 2(2): 66-73.

24. Nagpal K, Singh SK, Mishra DN. Chitosan nanoparticles: a promising system in novel drug delivery. *Chemical and Pharmaceutical Bulletin*, Nov 1, 2010; 58(11): 1423-30.
25. Pillai O, Panchagnula R. Polymers in drug delivery. *Current opinion in chemical biology*, Aug 1, 2001; 5(4): 447-51.
26. Barar J, Javadzadeh AR, Omid Y. Ocular novel drug delivery: impacts of membranes and barriers. *Expert opinion on drug delivery*, May 1, 2008; 5(5): 567-81.
27. Challa R, Ahuja A, Ali J, Khar RK. Cyclodextrins in drug delivery: an updated review. *Aaps Pharmscitech*, Jun 1, 2005; 6(2): E329-57.
28. Trotta F, Zanetti M, Cavalli R. Cyclodextrin-based nanosponges as drug carriers. *Beilstein journal of organic chemistry*, Nov 29, 2012; 8(1): 2091-9.
29. Poonia N, Kharb R, Lather V, Pandita D. Nanostructured lipid carriers: versatile oral delivery vehicle. *Future science OA.*, Jul 15, 2016; 2(3): FSO135.
30. Philip AK, Philip B. Colon targeted drug delivery systems: a review on primary and novel approaches. *Oman medical journal*, Apr, 2010; 25(2): 79.